论文部分内容阅读
目的:观察阿德福韦酯短期联合拉米夫定治疗失代偿乙肝肝硬化近期疗效和安全性。方法:58例失代偿期乙肝肝硬化患者(Child-PughB级45例,C级13例)随机分为两组,治疗组30例,阿德福韦酯10mg联合拉米夫定100mg,1次/d口服,3个月后停拉米夫定,单独服用阿德福韦酯。对照组28例,予保肝、利尿治疗。结果:治疗组48周时HBV-DNA阴转率为96.7%,对照组14.3%,两组比较有统计学差异。结论:阿德福韦酯短期联合拉米夫定治疗失代偿期乙肝肝硬化能快速抑制病毒复制,改善肝功能,降低变异率。
Objective: To observe the short-term efficacy and safety of adefovir dipivoxil combined with lamivudine in the treatment of decompensated hepatitis B cirrhosis. Methods: 58 patients with decompensated hepatitis B cirrhosis (Child-PughB 45 cases, C 13 cases) were randomly divided into two groups, the treatment group 30 cases, adefovir dipivoxil 10mg combined with lamivudine 100mg, 1 Oral / d orally, lamivudine stopped after 3 months, taking adefovir dipivoxil alone. Control group of 28 cases, to liver, diuretic treatment. Results: After 48 weeks of treatment, the negative conversion rate of HBV-DNA was 96.7% in the control group and 14.3% in the control group, with statistical difference between the two groups. Conclusion: Adefovir dipivoxil combined with lamivudine short-term treatment of decompensated hepatitis B cirrhosis can rapidly inhibit viral replication, improve liver function and reduce the mutation rate.